TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00723853

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reach-Out Program, nutritional and exercise program
Description: This group will participate in the Reach-Out nutritional and exercise program. This includes 14 weekly, group sessions involving both parents and children.~During these sessions, participants will receive hands-on education regarding food and exercise habits. Sample nutrition activities include learning to read nutrition labels on foods, a tour of a grocery store and practicing a recipe substituting low fat for high fat ingredients. Exercise activities involve physical activities appropriate for children and adults, respectively. Session leaders will help subjects set personal goals in the areas of nutrition and physical activity, and follow up on subjects' progress each week at sessions and with telephone calls between sessions. At the end of the 14-week program, subjects will be asked to attend four bi-monthly and 18 monthly follow-up sessions in which subjects will continue to meet as a group to work on goals in the areas of nutrition and exercise.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Reach-Out Program, nutritional and exercise program
Description: This group will participate in the Reach-Out nutritional and exercise program. This includes 14 weekly, group sessions involving both parents and children.~During these sessions, participants will receive hands-on education regarding food and exercise habits. Sample nutrition activities include learning to read nutrition labels on foods, a tour of a grocery store and practicing a recipe substituting low fat for high fat ingredients. Exercise activities involve physical activities appropriate for children and adults, respectively. Session leaders will help subjects set personal goals in the areas of nutrition and physical activity, and follow up on subjects' progress each week at sessions and with telephone calls between sessions. At the end of the 14-week program, subjects will be asked to attend four bi-monthly and 18 monthly follow-up sessions in which subjects will continue to meet as a group to work on goals in the areas of nutrition and exercise.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Reach-In Program, standard of care
Description: This group will received standard medical care for their health condition. This includes meeting individually with a dietician to learn about diet, exercise and diabetes. This also includes developing an individualized meal plan.
Study: NCT04116190

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telerehabilitation
Description: Short inpatient multidisciplinary rehabilitation followed by home-based telerehabilitation and a short evaluation period at the end of it.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conventional inpatient rehabilitation
Description: Multidisciplinary inpatient rehabilitation, no adjustments due to the study.
Study: NCT03537183

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise training
Description: 12 weeks, 3 hours a week, moderate intensity exercise training
Study: NCT02727504

Intervention type: DEVICE
Intervention: Electrocardiogram
Description: ECG at inclusion and M12

Intervention type: DEVICE
Intervention: 2D and 3D echocardiography
Description: 2D and 3D echocardiography at inclusion and M12

Intervention type: DEVICE
Intervention: Dobutamine stress echocardiography
Description: dobutamine stress echocardiography at inclusion

Intervention type: BIOLOGICAL
Intervention: Blood tests
Description: Blood test electrolytes, creatinine, hemoglobin, NT-proBNP, CRP, ST-2 at inclusion and M12

Intervention type: DEVICE
Intervention: Cardiac MRI
Description: Cardiac MRI at inclusion

Intervention type: DEVICE
Intervention: Cardiac scanner
Description: Cardiac scanner at inclusion

Intervention type: OTHER
Intervention: 6-minutes walking test
Description: 6-minutes walking test at inclusion and M12

Intervention type: OTHER
Intervention: Duke Activity Score
Description: Duke Activity Score at inclusion and M12
Study: NCT02804711

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Middle dosage of Staphylococcus aureus vaccine (30µg/0.6ml)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Middle dosage of Staphylococcus aureus vaccine (30µg/0.6ml)
Study: NCT05011331

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MedCline Shoulder Relief System
Description: Patients will receive a customized pillow to aid with sleep

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MedCline Shoulder Relief System
Description: Patients will receive a customized pillow to aid with sleep
Study: NCT02804711

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High dosage of Staphylococcus aureus vaccine (60µg/0.6ml)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High dosage of Staphylococcus aureus vaccine (60µg/0.6ml)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT00718250

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RFUSIN2-AML1
Description: AML cell vaccine alone. x4 doses 3 weeks apart

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Donor leukocyte infusion (DLI)
Description: 1 dose 1x107/kg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RFUSIN2-AML1 and donor leukocyte infusion
Description: AML cell vaccine x 4 doses 3 weeks apart Donor leukocyte infusion 1x107/kg x 1 dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RFUSIN2-AML1 and donor leukocyte infusion
Description: AML cell vaccine x4 doses 3 weeks apart Donor leukocyte infusion 1x108/kg x1 dose
Study: NCT00804986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2428757
Description: Once weekly for 12 weeks as a subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2428757
Description: Once weekly for 12 weeks as a subcutaneous injection.
Study: NCT02804711

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT00912925

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: rhIDU (recombinant human-Alpha-L-Iduronidase)
Description: Patients in the active treatment group received Aldurazyme intravenously at a dose of 100 units/kg (approximately 0.58mg/kg) administered intravenously over approximately 4 hours once weekly for 26 weeks.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients in the Placebo-control group were administered a solution of 100mM sodium phosphate , 150mM sodium chloride, and 0.001% polysorbate-80, adjusted to a pH of 5.8 administered intravenously over a time period of approximately 4 hours once weekly for 26 weeks.
Study: NCT01600690

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Statin withdrawal
Description: Patients are instructed to stop taking statin pills for the duration of the study. The rest of therapy will remain unchanged.
Study: NCT00511095

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HEPLISAV
Description: Intramuscular (IM) injections 0.5mL on Day 0 and Week 4
Study: NCT05552170

Intervention type: OTHER
Intervention: day-case surgery
Description: Patients who underwent loop ileostomy with age ≤ 65 and ASA II or III were enrolled and underwent ALIR after rigorous evaluation.
Study: NCT00804986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2428757
Description: Once weekly for 12 weeks as a subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2428757
Description: Once weekly for 12 weeks as a subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2428757
Description: Once weekly for 12 weeks as a subcutaneous injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 of 5 volumes of placebo given once weekly for 12 weeks as a subcutaneous injection.
Study: NCT02756546

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone
Study: NCT00467012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: 10mg/kg，Day1, 15 of 1 cycle(4 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: 10mg/kg，Day1, 15 of 1 cycle(4 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 90mg/ m2，Day1, 8, 15 of 1 cycle(4 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 90mg/ m2，Day1, 8, 15 of 1 cycle(4 weeks)
Study: NCT00278551

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immune ablation and hematopoietic stem cell transplant
Description: Autologous Hematopoietic Stem Cell Transplant
Study: NCT02347254

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial ExAblate
Description: Transcranial ExAblate MRgFUS
Study: NCT00509938

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: human lactoferrin peptide 1-11
Description: Each subject will receive a single intravenous dose of hLF1-11 given in a volume of 20mL given over 20 minutes i.e. 1mL/per minute.
Study: NCT01853852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GR181413A/AT1001 solution
Description: Powder for reconstitution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GR181413A/AT1001 solution
Description: Powder for reconstitution
Study: NCT03560232

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefazolin + Gentamicin
Description: See arm description

Intervention type: DRUG
Group type: OTHER
Intervention: Clindamycin + Gentamicin
Description: See arm description
Study: NCT01853852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GR181413A/AT1001 capsule
Description: Size 2, hard gelatin capsule, white opaque / blue opaque
Study: NCT02387645

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lavage of the Uterus
Description: The lavage will be performed in the operating theatre under general anesthesia. The ALPINE technique includes the following steps. A three way catheter (catheter for uterine and tubal lavage) is inserted into the cervical canal and a balloon is inflated to seal the cervical canal. The patient is put into anti-Trendellenburg positioning. Normal saline is slowly flushed into the uterine cavity and proximal tubes. After the lavage is finished, the balloon is deflated and the catheter is removed. A cap is put on the collection syringe and the syringe is sent to the laboratory.
Study: NCT03152071

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Robot assited thoracic surgery
Description: The lobectomy will be preformed in case of an operable lung cancer. The thoracic surgery technique used is robot assisted thoracic surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Video assited thoracic surgery
Description: The lobectomy will be preformed in case of an operable lung cancer. The thoracic surgery technique used is video assisted thoracic surgery.
Study: NCT04397783

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: construction of an end colostomy
Description: longitudinal incision in the construction of an end colostomy
Study: NCT00674245

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pantoprazole
Description: 40 mg once daily for 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pantoprazole
Description: 40 mg once daily improves sleep quality in patients with GERD.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 40 mg once daily for 4 weeks
Study: NCT01690572

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel coated balloon catheter
Description: Dilatation of the target lesion
Study: NCT03101683

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Partial chest wall radiation therapy
Description: A dose of 40 Gy in 16 fractions (2.5 Gy per fraction) is delivered in the area at risk of local recurrence (skin and the pectoralis muscles) delineated by surgical clips and 3D-MRI reconstruction for a precise localization of the tumor excised
Study: NCT04113005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desmopressin
Description: To evaluate the safety and tolerability of Desmopressin in CRPC subjects starting Docetaxel treatment. Additionally, CTCs will be collected before and after Desmopressin/Docetaxel treatment to evaluate therapeutic efficacy.
Study: NCT01690572

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: uncoated balloon catheter sprinter legend
Description: Dilatation of the target lesion
Study: NCT02426996

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scan of shoulder
Description: A scan (no injection) of the concerned shoulder will be performed at 3 months post-surgery. Cuts in three planes of space, including all of the glenoid. 3D reconstructions.
Study: NCT02291094

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Patients in intravenous lidocaine group received an intravenous bolus injection of 2 mg/kg lidocaine followed by a continuous lidocaine infusion of 3 mg/kg/hr.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: Patients in remifentanil group received an intravenous bolus injection of 2 mg/kg lidocaine followed by a continuous remifentanil infusion of 0,1 mcg/kg/min.
Study: NCT02273999

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: RecoveryRx™
Description: Appliance of the device after surgery

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RecoveryRx™
Description: Appliance of the device after surgery
Study: NCT02018900

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ecologic 825/scFOS

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01988649

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intranasal Oxytocin
Description: Administration of intranasal Oxytocin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (saline)
Description: Administration of normal saline intranasally.
Study: NCT02926794

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SA and II
Description: Self affirmation intervention where participants rank 11 values, then write about why their top ranked value is important AND Implementation intentions intervention where participants form two implementation intentions (If/then) statements regarding drinking behavior and write why these are important

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SA and No II
Description: Self affirmation intervention where participants rank 11 values, then write about why their top ranked value is important AND No implementation intentions intervention where participants write why selected health strategies are important (and do nothing else)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No SA and II
Description: Control writing intervention where participants rank 11 values, then write about why their 10th ranked value is important to someone else AND Implementation intentions intervention where participants form two implementation intentions (If/then) statements regarding drinking behavior and write why these are important

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No SA and No II
Description: Control writing intervention where participants rank 11 values, then write about why their 10th ranked value is important to someone else AND No implementation intentions intervention where participants write why selected health strategies are important (and do nothing else)
Study: NCT00754065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027)
Description: Estradiol valerate (EV) and dienogest (DNG). Sequential 4-phasic regimen. Daily oral administration of one encapsulated BAY86-5027 for 28 days per Cycle, for 13 treatment cycles: Days 1-2, 3.0 mg EV; Days 3-7, 2.0 mg EV+2.0 mg DNG; Days 8-24, 2.0 mg EV+3.0 mg DNG; Days 25-26, 1.0 mg EV; Days 27-28, placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ortho Tri Cyclen Lo
Description: Dose--Ethinylestradiol (EE) + Norgestimate (NGM) Triphasic 21-day regimen. Daily oral administration of one encapsulated Ortho Tri-Cyclen Lo for 28 days per Cycle, for 13 treatment cycles: Days 1-7, 0.025 mg EE+0.180 NGM; Days 8-14, 0.025 mg EE+0.215 NGM; Days 15-21, 0.025 mg EE+0.250 NGM; Days 27-28, placebo
Study: NCT01853852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GR181413A/AT1001 capsule
Description: Size 2, hard gelatin capsule, white opaque / blue opaque

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GR181413A/AT1001 capsule
Description: Size 2, hard gelatin capsule, white opaque / blue opaque

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Potable water
Description: Matched, Size 2, hard gelatin capsule, white opaque/blue opaque

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Potable water
Description: Matched, Size 2, hard gelatin capsule, white opaque/blue opaque

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo capsule
Description: Solution matched

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule
Description: Solution matched
Study: NCT03484988

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oil
Description: The participants were asked to take corn oil capsule twice a day, 4 capsules (500mg/capsules) each time. The intervention period is about 3 months. Do not take any other medicine, traditional Chinese medicine, or dietary supplements.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Echium oil
Description: The participants were asked to take echium oil capsule twice a day, 4 capsules (500mg/capsules) each time. The intervention period is about 3 months. Do not take any other medicine, traditional Chinese medicine, or dietary supplements.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mixed oil
Description: The participants were asked to take mixed oil(echium oil,camelina oil,safflower oil) twice a day, 4 capsules (500mg/capsules) each time. The intervention period is about 3 months. Do not take any other medicine, traditional Chinese medicine, or dietary supplements.
Study: NCT03971851

Intervention type: OTHER
Intervention: Frailty risk groups
Description: Patients older than 65 will be separated into groups of varying frailty risk

Intervention type: OTHER
Intervention: Frailty risk groups
Description: Patients older than 65 will be separated into groups of varying frailty risk
Study: NCT02940860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron isomaltoside/ferric derisomaltose
Description: Iron isomaltoside/ferric derisomaltose (Monofer®/Monoferric®; 100 mg/mL) was the test product in this trial.~The dose of iron isomaltoside/ferric derisomaltose for the individual subject was set to 1000 mg. The dose was diluted in 100 mL 0.9 % sodium chloride (100 mL bags) and administered as a single IV infusion over approximately 20 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron sucrose
Description: Iron sucrose (Venofer®; 20 mg elemental iron/mL) was the comparator in this trial. Iron sucrose was administered as 200 mg undiluted IV injections over approximately 2-5 minutes and repeated according to standard practice or physician choice up to a maximum of five times within the first two weeks starting at baseline. A cumulative dose of 1000 mg was recommended.
Study: NCT04314492

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tonsillectomy
Description: Intracapsular removal of tonsillar tissue (\>90%) with coblation
Study: NCT04556201

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SOLTIVE™ Premium SuperPulsed Laser Fiber System
Description: SOLTIVE™ SuperPulsed Laser Fiber System and SOLTIVE™ Laser Fibers for single-use only
Study: NCT02910089

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Shared Decision Making
Description: This prospective study will include 700 beneficiaries of Horizon Blue Cross Blue Shield of New Jersey (BCBSNJ).
Study: NCT02470429

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SYSTANE HYDRATION lubricant eye drops
Description: Preserved with POLYQUAD (polidronium chloride) 0.001%

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hyabak 0.15% eye drops
Description: Preservative-free

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% saline eye drops
Description: Preservative-free, one drop 4 times a day in each eye (run-in period)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.9% saline eye drops
Description: Preservative-free, one drop 4 times a day in each eye (run-in period)
Study: NCT01973972

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight management
Description: Weight management group visits using low-carbohydrate diet followed for weight management.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Shared medical appointments (SMA)
Description: Diabetes management group visits for diabetes management.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Shared medical appointments (SMA)
Description: Diabetes management group visits for diabetes management.
Study: NCT01438359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA21 and Furosemide with food
Description: The maximum dose of PA21 will be 15.0 g/day. The maximum dose of Furosemide will be 40 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: No PA21; Furosemide with food
Description: The maximum dosage of Furosemide will be 40 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA21 with food and Furosemide 2hrs later
Description: The maximum dose of PA21 will be 15 g/day. The maximum dose of Furosemide will be 40 mg/day
Study: NCT03582436

Intervention type: PROCEDURE
Intervention: Kidney transplantation
Description: For the patients with the kidney transplantation, these parameters will be analysis:~Transcriptomics analysis Characteristics of anti HLA DSA analysis Non-HLA antibodies analysis Omics blood analysis Urine chemokines analysis